130 related articles for article (PubMed ID: 1200701)
1. Lymphocyte stimulation in the cellular inflammatory reaction of some human skin tumours.
Pullmann H; Steigleder GK
Arch Dermatol Res (1975); 1975 Oct; 253(3):219-24. PubMed ID: 1200701
[TBL] [Abstract][Full Text] [Related]
2. Sequential studies on cell-mediated tumor immunity and blocking serum activity in ten patients with malignant melanoma.
Hellström I; Warner GA; Hellström KE; Sjögren HO
Int J Cancer; 1973 Mar; 11(2):280-92. PubMed ID: 4790696
[No Abstract] [Full Text] [Related]
3. Differentiation between B cells, T cells, and histiocytes in melanocytic lesions: primary and metastatic melanoma and halo and giant pigmented nevi.
Edelson RL; Hearing VJ; Dellon AL; Frank M; Edelson EK; Green I
Clin Immunol Immunopathol; 1975 Nov; 4(4):557-68. PubMed ID: 1081937
[No Abstract] [Full Text] [Related]
4. Epithelial distribution of a myelomonocytic antigen LI in relation to cutaneous malignancies and melanocytic naevi.
Gabrielsen TO; Brandtzaeg P; Hoel PS; Dale I
Br J Dermatol; 1988 Jan; 118(1):59-67. PubMed ID: 3277660
[TBL] [Abstract][Full Text] [Related]
5. Immunoperoxidase localization of lymphocyte subsets in the host response to melanoma and nevi.
Kornstein MJ; Brooks JS; Elder DE
Cancer Res; 1983 Jun; 43(6):2749-53. PubMed ID: 6342758
[TBL] [Abstract][Full Text] [Related]
6. A study of cellular inflammatory reaction in human malignant melanoma, using in vitro-labelling techniques with h3-thymidine.
Pullmann H; Steigleder GK
Arch Dermatol Forsch; 1974 Apr; 249(3):285-89. PubMed ID: 4840894
[No Abstract] [Full Text] [Related]
7. The halo naevus and malignant melanoma.
Lancet; 1973 May; 1(7810):982. PubMed ID: 4121601
[No Abstract] [Full Text] [Related]
8. Comparison of cell-mediated immunity to melanoma cells in patients with vitiligo, halo nevi or melanoma.
Mitchell MS; Nordlund JJ; Lerner AB
J Invest Dermatol; 1980 Aug; 75(2):144-7. PubMed ID: 7410884
[No Abstract] [Full Text] [Related]
9. The differential reactivity of benign and malignant nevomelanocytic lesions with mouse monoclonal antibody TNKH1.
Nakanishi T; Hashimoto K
Cancer; 1987 Apr; 59(7):1340-4. PubMed ID: 3545436
[TBL] [Abstract][Full Text] [Related]
10. FAS, FAS ligand, tumor infiltrating lymphocytes, and macrophages in malignant melanoma: an immunohistochemical study.
Bozdogan N; Bozdogan O; Pak I; Atasoy P
Int J Dermatol; 2010 Jul; 49(7):761-7. PubMed ID: 20618494
[TBL] [Abstract][Full Text] [Related]
11. Expression of Thy-1 antigen on human melanoma cells.
Hersey P; Grace J; Murray E; Palmer A; McCarthy WH
Int J Cancer; 1983 Jul; 32(1):21-5. PubMed ID: 6134683
[TBL] [Abstract][Full Text] [Related]
12. In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin.
Poppema S; Bröcker EB; de Leij L; Terbrack D; Visscher T; Ter Haar A; Macher E; Thé TH; Sorg C
Clin Exp Immunol; 1983 Jan; 51(1):77-82. PubMed ID: 6219841
[TBL] [Abstract][Full Text] [Related]
13. [Delayed hypersensitivity reaction in malignant melanoma].
Gorodilova VV; Saraeva ZM; Slesareva RI; Monzul' GD
Vopr Onkol; 1973; 19(3):23-7. PubMed ID: 4762691
[No Abstract] [Full Text] [Related]
14. Immunological associations of the halo naevus with cutaneous malignant melanoma.
Copeman PW; Lewis MG; Phillips TM; Elliott PG
Br J Dermatol; 1973 Feb; 88(2):127-37. PubMed ID: 4574770
[No Abstract] [Full Text] [Related]
15. Antigens associated with tumor progression in melanocytic neoplasia.
Elder DE; Herlyn M
Pigment Cell Res; 1992; Suppl 2():136-43. PubMed ID: 1409415
[No Abstract] [Full Text] [Related]
16. Malignant melanoma in renal-transplant recipients.
Greene MH; Young TI; Clark WH
Lancet; 1981 May; 1(8231):1196-9. PubMed ID: 6112537
[TBL] [Abstract][Full Text] [Related]
17. DIFFERENTIATION OF NEVOID BASAL CELL CARCINOMA FROM EPITHELIOMA ADENOIDES CYSTICUM: A CLINICOPATHOLOGIC AND HISTOCHEMICAL STUDY.
GRAHAM JH; MASON JK; GRAY HR; HELWIG EB
J Invest Dermatol; 1965 Mar; 44():197-200. PubMed ID: 14275696
[No Abstract] [Full Text] [Related]
18. Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections.
Imam A; Mitchell MS; Modlin RL; Taylor CR; Kempf RA; Kan-Mitchell J
J Invest Dermatol; 1986 Feb; 86(2):145-8. PubMed ID: 3528308
[TBL] [Abstract][Full Text] [Related]
19. The immune response in halo nevi.
Zeff RA; Freitag A; Grin CM; Grant-Kels JM
J Am Acad Dermatol; 1997 Oct; 37(4):620-4. PubMed ID: 9344203
[TBL] [Abstract][Full Text] [Related]
20. Halo nevus: competent surveillance of potential melanoma?
Krebs JA; Roenigk HH; Deodhar SD; Barna B
Cleve Clin Q; 1976; 43(1):11-5. PubMed ID: 1261030
[No Abstract] [Full Text] [Related]
[Next] [New Search]
